IN2015DN03925A - - Google Patents

Info

Publication number
IN2015DN03925A
IN2015DN03925A IN3925DEN2015A IN2015DN03925A IN 2015DN03925 A IN2015DN03925 A IN 2015DN03925A IN 3925DEN2015 A IN3925DEN2015 A IN 3925DEN2015A IN 2015DN03925 A IN2015DN03925 A IN 2015DN03925A
Authority
IN
India
Prior art keywords
antigens
virus
chimeric
hcv
vaccine compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Carrera Santiago Dueñas
Noriega Daylen Aguilar
Cañizares Yalena Amador
Lajonchere Ponce De León Liz Alvarez
Donato Gillian Martínez
Blanco Sonia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of IN2015DN03925A publication Critical patent/IN2015DN03925A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3925DEN2015 2012-11-05 2013-10-28 IN2015DN03925A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
IN2015DN03925A true IN2015DN03925A (enExample) 2015-10-02

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3925DEN2015 IN2015DN03925A (enExample) 2012-11-05 2013-10-28

Country Status (15)

Country Link
US (1) US9676825B2 (enExample)
EP (1) EP2915544B1 (enExample)
JP (1) JP6259831B2 (enExample)
KR (1) KR102093495B1 (enExample)
CN (1) CN104837498B (enExample)
AR (1) AR093341A1 (enExample)
AU (1) AU2013339846B2 (enExample)
CA (1) CA2901346C (enExample)
CU (1) CU24112B1 (enExample)
ES (1) ES2644801T3 (enExample)
IN (1) IN2015DN03925A (enExample)
MX (1) MX358507B (enExample)
RU (1) RU2639504C2 (enExample)
WO (1) WO2014067498A1 (enExample)
ZA (1) ZA201503036B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986342C (en) 2015-07-07 2024-04-02 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
US11596679B2 (en) * 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039715D1 (de) 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド Hcv特異的なt細胞の活性化
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
US20110110974A1 (en) 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
JP5593220B2 (ja) * 2008-04-25 2014-09-17 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
EP2331125A4 (en) * 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
KR102093495B1 (ko) 2020-03-26
JP6259831B2 (ja) 2018-01-10
US20150307558A1 (en) 2015-10-29
CU24112B1 (es) 2015-08-27
KR20150079694A (ko) 2015-07-08
EP2915544B1 (en) 2017-08-09
JP2015536936A (ja) 2015-12-24
AU2013339846B2 (en) 2017-08-17
MX358507B (es) 2018-08-22
US9676825B2 (en) 2017-06-13
MX2015005651A (es) 2015-08-20
CN104837498B (zh) 2018-05-18
CN104837498A (zh) 2015-08-12
CU20120153A7 (es) 2014-06-27
ES2644801T3 (es) 2017-11-30
CA2901346A1 (en) 2014-05-08
ZA201503036B (en) 2016-01-27
WO2014067498A1 (es) 2014-05-08
RU2639504C2 (ru) 2017-12-21
AR093341A1 (es) 2015-06-03
RU2015121429A (ru) 2016-12-27
AU2013339846A1 (en) 2015-05-14
EP2915544A1 (en) 2015-09-09
CA2901346C (en) 2019-04-23

Similar Documents

Publication Publication Date Title
IN2014DN10288A (enExample)
PH12017500727A1 (en) Modified virus-like particles of cmv
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12018501047A1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
IN2014KN03063A (enExample)
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2015134722A3 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
MX391149B (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
MX2019007924A (es) Vacunas contra la influenza.
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
IN2014DN09445A (enExample)
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
WO2016012406A3 (en) Attenuated strain of prrs and potential use in immunising preparations
MX2015011485A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2016141201A3 (en) Rational vaccine design for hepatitis c virus
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).
WO2015171505A3 (en) Antigens of pneumocystis murina and uses thereof
MX358496B (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.